Resources
9 Results (showing 1 - 9)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/30/2021 (updated 4/5/2024)
This toolkit provides correctional administrators and health care providers the information necessary to plan and implement MAT programs within jails and prisons.
Posted 3/25/2021 (updated 4/5/2024)
Care Coordination: Navigating Individuals With OUD Through a Treatment and Recovery Continuum
Presenters from the Western Region will describe two innovative care coordination strategies and models from the RCORP/Rural Health Opioid Program grantee perspective.
Posted 3/3/2021 (updated 4/5/2024)
The National Governors Association and the American Correctional Association recently released a new toolkit on "Expanding Access to Medications for Opioid Use Disorder in Corrections and Community Settings: A Roadmap for States to Reduce Opioid Use Disorder for People in the Justice System."
This roadmap highlights existing state efforts and serves as a policy development tool for Governors and state officials seeking to improve coordination and bolster existing efforts across state agencies to address OUD among people involved in the justice system by expanding access to evidence-based medications. The following are key steps for supporting MOUD in corrections settings.
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.
Posted 7/19/2021 (updated 4/2/2024)
Drug overdose deaths in the United States hit a record high in 2017, with an estimated 72,000 deaths. Over two-thirds of those deaths, roughly 47,600, were due to opioids.These staggering numbers continued in 2018, as over 67,000 drug overdose deaths occurred, and opioids were involved in rough 46,800 of those overdose deaths.
This roadmap highlights existing state efforts and serves as a policy development tool for Governors and state officials seeking to improve coordination and bolster existing efforts across state agencies to address OUD among people involved in the justice system by expanding access to evidence-based medications.
Posted 1/28/2020 (updated 3/28/2024)
The following guidelines introduce what has been learned from the sheriffs’ and jail administrators’ innovative use of MAT, describing the essential components of these programs and analyzing the latest research on how these programs are best implemented, as well as the medications approved for opioid use disorders.
Posted 12/30/2019 (updated 3/28/2024)
Preventing Deaths, Reducing Risk to Counties and States
Posted 6/16/2020 (updated 3/28/2024)
The most effective therapy for people with opioid use disorder involves the use of Food and Drug Administration-approved medications—methadone, buprenorphine, and naltrexone. Despite evidence that this approach, known as medications for opioid use disorder, reduces relapse and saves lives, the vast majority of jails and prisons do not offer this treatment.
Posted 7/26/2023 (updated 3/28/2024)
Just 5 years ago, only 1% of jails and prisons provided MOUD, but this practice has flourished. Dr. Costello discussed the emerging evidence base for MOUD in jails, regulatory changes, funding opportunities, and the dramatic increase in usage of MOUD in our nation's correctional facilities.